Seattle Startup Nexgenia Raises $2M to Broaden Polymer Reagent Technology for Immunotherapy Applications

Seattle biotech startup Nexgenia, led by CEO Ron Myers, raised $2 million to expand its polymer-based reagents for sorting cells in immunotherapy production to new applications. The funding, led by the W Fund and Washington Research Foundation, will support further research into diverse uses of their technology beyond cancer treatment.